tetano
Editor, Senior Moderator
Pediatr Allergy Immunol. 2020 Apr 22. doi: 10.1111/pai.13262. [Epub ahead of print]
Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.
Brough HA[SUP]1[/SUP], Kalayci O[SUP]2[/SUP], Sediva A[SUP]3[/SUP], Untersmayr E[SUP]4[/SUP], Munblit D[SUP]5,[/SUP][SUP]6[/SUP], Rodriquez Del Rio P[SUP]7[/SUP], Vazquez-Ortiz M[SUP]6[/SUP], Arasi S[SUP]8[/SUP], Alvaro-Lozano M[SUP]9[/SUP], Tsabouri S[SUP]10[/SUP], Galli E[SUP]11[/SUP], Beken B[SUP]12[/SUP], Eigenmann PA[SUP]13[/SUP].
Author information
Abstract
While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and health care providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, bronchodilators increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; allergy; asthma; biologics; children; coronavirus; corticosteroids; immunodeficiency; treatment
PMID:32319129DOI:10.1111/pai.13262
Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.
Brough HA[SUP]1[/SUP], Kalayci O[SUP]2[/SUP], Sediva A[SUP]3[/SUP], Untersmayr E[SUP]4[/SUP], Munblit D[SUP]5,[/SUP][SUP]6[/SUP], Rodriquez Del Rio P[SUP]7[/SUP], Vazquez-Ortiz M[SUP]6[/SUP], Arasi S[SUP]8[/SUP], Alvaro-Lozano M[SUP]9[/SUP], Tsabouri S[SUP]10[/SUP], Galli E[SUP]11[/SUP], Beken B[SUP]12[/SUP], Eigenmann PA[SUP]13[/SUP].
Author information
Abstract
While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and health care providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, bronchodilators increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; allergy; asthma; biologics; children; coronavirus; corticosteroids; immunodeficiency; treatment
PMID:32319129DOI:10.1111/pai.13262